Cagrilintide vs Liraglutide
A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Cagrilintide
Long-acting amylin/CGRP receptor co-agonist developed by Novo Nordisk. Reduces food intake and body weight via central satiety pathways distinct from the GLP-1 pathway. In the CagriSema combination trial with semaglutide, the combination achieved up to ~25% weight reduction — substantially greater than either agent alone.
Full profileLiraglutide
Liraglutide is a once-daily GLP-1 receptor agonist — the first long-acting GLP-1 analog approved for both type 2 diabetes (Victoza, 1.8mg) and chronic weight management (Saxenda, 3mg). It was the foundational GLP-1 agonist that established the class's cardiovascular benefits and set the stage for semaglutide and tirzepatide.
Full profile| Cagrilintide | Liraglutide | |
|---|---|---|
| Category | GLP-1 & Metabolic | GLP-1 & Metabolic |
| Also known as | AM833, amylin analogue, CagriSema partner | NN2211, Victoza, Saxenda |
| Evidence | Investigational (in trials) | FDA-approved |
| Dosing range | 0.3mg–2.4mg mg, once weekly subcutaneous | 0.6mg–3.0mg mg, Once daily subcutaneous injection |
| Administration | Subcutaneous injection | Subcutaneous injection (abdomen, thigh, or upper arm) |
| Key side effects | Nausea, Vomiting, Injection site reactions, Decreased appetite | Nausea (most common, especially during initiation), Vomiting, Diarrhea, Decreased appetite |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: Cagrilintide is investigational (in trials), while Liraglutide is fda-approved.
- Administration: Cagrilintide — Subcutaneous injection; Liraglutide — Subcutaneous injection (abdomen, thigh, or upper arm).
- Frequency: Cagrilintide is typically once weekly subcutaneous; Liraglutide is Once daily subcutaneous injection.
How each works
Cagrilintide
Cagrilintide activates amylin receptors (RAMP/CTR complexes) in the area postrema and hypothalamus, reducing food intake and slowing gastric emptying through mechanisms independent of GLP-1 signaling. This non-overlapping pathway allows combination with semaglutide without compounding GI side effects. Phase 2 CagriSema data showed 15–25% weight loss at 32 weeks, supporting the complementary mechanism hypothesis.
Liraglutide
The LEADER trial (N=9340) demonstrated significant reduction in major adverse cardiovascular events (MACE) in high-risk T2D patients — the first cardiovascular outcomes trial for a GLP-1 agonist. The SCALE trials showed 5–8% mean weight loss at 3mg/day vs placebo. While superseded by semaglutide and tirzepatide in weight loss efficacy, liraglutide has the longest safety record in the class (approved 2010) and daily dosing allows finer tolerability titration.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.